In other studies, researchers demonstrated the use of granzyme B-specific (GZP-PET) imaging to monitor changes in effector cell activation in response to treatment with paclitaxel (PTX) and immunological inhibitors in a mouse model of triple-negative breast cancer [54]. Here, GZMB is linked to triple-negative breast carcinoma.